New Delhi, Mar 18 (PTI) Zydus Lifesciences Ltd on Tuesday said it has received final approval from the US health regulator to manufacture a generic version of Apalutamide tablets used in the treatment of prostate cancer.

The approval by the US Food and Drug Administration (USFDA) is to manufacture Apalutamide tablets of 60 mg strength, Zydus Lifesciences said in a regulatory filing.

Also Read | News Headlines for School Assembly Today, 19 March 2025: Check Important National, International, Sports, Entertainment and Business Stories.

The approved Apalutamide tablets will be produced at Zydus Lifesciences (SEZ), Ahmedabad, it added.

Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer.

Also Read | 7th Pay Commission: AICPI-IW Drops 0.5 Points Before Expected DA Hike for Central Govt Employees.

It had annual sales of USD 1,099.8 million in the US, the company said, citing IQVIA MAT January 2025 data.

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)